Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib and BMS-986345 in Lymphoid Malignancy
NCT05065866Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine in lymphoid malignancy, sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose up to 26 months. Started Nov 2021; status: completed.
02
Drugs
azacitidine
03
Conditions
lymphoid malignancy
Beyond the preview
Go deeper on NCT05065866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065866.